Sign in →

Test Code PARV Parvovirus B19 Antibodies, IgG and IgM, Serum

Reporting Name

Parvovirus B19 Ab, IgG and IgM, S

Useful For

Diagnosing recent parvovirus infection (IgM)


Assessing past infection (eg, screening pregnant women) and immunity to parvovirus infection (IgG)

Profile Information

Test ID Reporting Name Available Separately Always Performed
PAIG Parvovirus B19 Ab, IgG, S No Yes
PAIM Parvovirus B19 Ab, IgM, S No Yes

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type


Specimen Required


Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 14 days
  Frozen  14 days
  Ambient  7 days

Reference Values

IgG: <0.9

IgM: <0.9

Day(s) and Time(s) Performed

Monday through Friday; 11 a.m.

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86747 x 2

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PARV Parvovirus B19 Ab, IgG and IgM, S In Process


Result ID Test Result Name Result LOINC Value
PAIG Parvovirus B19 Ab, IgG, S 7983-0
PAIMS Parvovirus B19 Ab, IgM, S 7984-8
INT20 Interpretation 59464-8

Clinical Information

Parvovirus B19 is the causative agent of fifth disease (erythema infectiosum, slapped cheek syndrome), which usually produces a mild illness characterized by an intensive erythematous maculopapular facial rash. Most outbreaks of parvovirus infection are acquired by direct contact with respiratory secretions and occur in the spring of the year. Close contact between individuals is responsible for infection in schools, daycare centers, and hospitals. The virus has also been associated with fetal damage (hydrops fetalis), aplastic crisis, and arthralgia.(2-4) Infection during pregnancy risks transmission to the fetus, which may cause intrauterine death. The rate of fetal death following maternal infection ranges between 1% and 9%.


Specimens with an index of <0.9 are considered negative.


Specimens with an index of >1.1 are considered positive.


Specimens with an index between 0.9 and 1.1, inclusive, are considered equivocal.


Parvovirus B19 IgM

Parvovirus B19 IgG




Implies no past infection/patient may be susceptible to B19V infection



Implies past exposure/infection-minimal risk of B19V infection


Positive or negative

May indicate current or recent B19V infection-retest in 1 to 2 weeks



Implies current or recent B19V infection


Negative or equivocal

May indicate current B19V infection-retest in 1 to 2 weeks


The presence of IgM class antibodies indicates recent infection. The presence of IgG antibodies only is indicative of past exposure.


Both IgG and IgM may be present at or soon after onset of illness and reach peak titers within 30 days. Because IgG antibody may persist for years, diagnosis of acute infection is made by the detection of IgM antibodies.


The prevalence of parvovirus B19 IgG antibodies increases with age. The age-specific prevalence of antibodies to parvovirus is 2% to 9% of children under 5 years, 15% to 35% in children 5 to 18 years of age, and 30% to 60% in adults (19 years or older).

Clinical Reference

1. Brown KE, Young NS: Parvovirus B19 in human disease. Ann Rev Med 1997;48:59-67

2. Markenson GR, Yancey MK: Parvovirus B19 infections in pregnancy. Semin Perinatol 1998;22(4):309-317

3. Summers J, Jones SE, Anderson MJ: Characterization of the genome of the agent of erythrocyte aplasia permits its classification as a human parvovirus. J Gen Virol 1983;64;(Pt 11):2527-2532

Analytic Time

Same day/1 day

Reject Due To


Mild OK; Gross reject


Mild OK; Gross reject


Mild OK; Gross reject



Method Name

Enzyme Immunoassay (EIA)


If not ordering electronically, complete, print, and send a General Request Form (T239) with the specimen (